CRU Hungary Kft.

Encs 44 trials 8 recruiting

44 Registered trials

8 Currently recruiting

Organisation

CRU Hungary Kft.

Location

Encs, Hungary

Identifier

ORG-100040770

Address

Thokoly Utca 15, Felsogod, 2132, Hungary

Departments

-
3301: Phase I. Clinical Pharmacology Trial Site
3302: NAP
CRU Hungary Kft
CRU Hungary Kft.
CRU Hungary Ltd
Dermatology
Early Phase Unit
N/A
NA

Clinical trials at this site (44)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Li… Recruiting

2025-523847-36-00 Participants with Mild, Moderate, or Severe Hepatic Imp 3 2026-05-19
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
Pharmacokinetics of NTRX-07 in fed and fasted participants Recruiting

2025-523695-23-00 Not applicable (trial is a pharmacokinetic study in hea 3 2025-12-11
A Study of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment Recruiting

2025-521947-19-00 Healthy, Hepatic Insufficiency 3 2025-11-19
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of R… Recruiting

2025-520754-11-00 Parkinson's disease 3 2025-08-25
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Late… Recruiting

2023-507195-43-00 Amyotrophic Lateral Sclerosis (ALS) 3 2024-07-01
A Study to Find Out How Safe and Effective AZD0780 Is for Adults with High 'Bad' Cholesterol from an Inherited Condition Ended

2025-520520-17-00 Heterozygous familial hypercholesterolaemia 5 2025-09-05
A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended

2025-520521-21-00 Hyperlipidemia 5 2025-09-02
A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liv… Ended

2024-520315-40-00 Normal Hepatic Function and Mild, Moderate, or Severe H 3 2025-07-22
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT… Ended

2024-515523-11-00 Chronic Weight Management 5 2025-06-09
A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary ef… Ended

2024-515907-20-00 Primary biliary cholangitis (PBC) 9 2025-05-23
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mell… Ended

2024-513539-25-00 Type 2 Diabetes Mellitus 4 2024-11-22
A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Ended

2023-508039-29-00 Moderate-to-severe Asthma 4 2024-09-16
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Respo… Ended

2023-505477-33-00 Psoriatic Arthritis 5 2019-06-18
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth… Ended

2022-501017-31-00 Rheumatoid arthritis 5 2016-05-10
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4… Ended

2024-516840-24-00 Chronic Kidney disease 3 2025-03-05
A Phase IIb Two-Cohort, Randomised, Placebo controlled, Double blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Ch… Ended

2023-510148-19-00 Chronic Heart Failure 4 2024-07-03
A Phase 3 study to assess efficacy and safety of oral tebipenem compared to IV imipenem-cilastatin in adults with cUTI/AP Ended

2023-503785-22-00 complicated urinary tract infection (cUTI) or acute pye 5 2024-03-25